About Arcturus Therapeutics Holdings Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://arcturusrx.com/
Frequently Asked Questions
What is the 52-week range for ARCT?
The 52-week high is $24.17 and the 52-week low is $5.5.
What is the P/E ratio for ARCT?
The P/E ratio data is currently unavailable.
What is the dividend yield for ARCT?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -46.54%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -317.62%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.81.
Analyst Recommendation Trends
Wall Street analyst consensus for ARCT over the last few months:
Latest ARCT News
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform
Arcturus Therapeutics (NASDAQ:ARCT) presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase, or OTC, deficiency, while outlining plans to introduce a next-generation delivery platform into the program. OTC deficiency is a urea-cycle disorder i
Why Is Arcturus Therapeutics Stock Gaining Thursday?
Arcturus Therapeutics (ARCT) surged over 6% after sharing positive Phase 2 interim data for its OTC deficiency drug, ARCT-810.
Microsoft reinstated, Ralph Lauren upgraded: Wall Street's top analyst calls
Microsoft reinstated, Ralph Lauren upgraded: Wall Street's top analyst calls
Citigroup Upgrades Arcturus Therapeutics to Buy, Raises Price Target to $20
Citigroup analyst Yigal Nochomovitz upgrades Arcturus Therapeutics (NASDAQ:ARCT) from Neutral to Buy and raises the price target from $8 to $20.
Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday
Nasdaq fell 150+ points, while Everpure jumped 14% after unveiling growth plans and a FY2028 outlook; other stocks also gained.
BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $20
BTIG analyst Thomas Shrader maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target from $23 to $20.
Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket
GlucoTrack surged 117.7% premarket after Lokahi Therapeutics signed its first external partnership; other stocks saw notable gains and losses.
Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform - Slideshow
2026-09-24. The following slide deck was published by Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform September 23, 2026...
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
SAN DIEGO, September 23, 2026--Arcturus Therapeutics Holdings Inc. (the "Company," "Arcturus," Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced encouraging interim Phase 2 results from ARCT-810 in ornithine transcarbamylase (OTC) deficiency and introduced LUNAR 2.0™, the Company’s next-generation mRNA delivery platform, and additional liver pipeline programs.
Arcturus Therapeutics Says ARCT-810 Generally Safe And Well Tolerated, Demonstrating Encouraging Activity Across Key Urea Cycle Biomarkers In Ongoing Phase 2 Study
Arcturus Therapeutics Holdings Inc. ((the "Company, " "Arcturus, NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced encouraging
Arcturus To Acquire myNEO, An AI Discovery Company, To Improve mRNA Design Quality, Accelerate Innovation, And Enhance Target Identification Capability; No Financial Terms Disclosed; Co To Host Presentation At 4:30 p.m. ET today
Arcturus to Acquire myNEOArcturus has entered into a definitive agreement to acquire myNEO, subject to customary closing conditions. The transaction is expected to close in October. Arcturus has been working closely
Arcturus Therapeutics Announces Interim Phase 2 Results From ARCT-810 In OTC Deficienc And Introduces LUNAR 2.0
ARCT-810 generally safe and well tolerated, demonstrating encouraging activity across key urea cycle biomarkers in ongoing Phase 2 studyLUNAR 2.0™ produces greater than 30-fold higher protein expression in multiple NHP
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
SAN DIEGO, September 18, 2026--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will host a virtual presentation on Wednesday, September 23, 2026, at 4:30 p.m. ET.
Arcturus Therapeutics To Present Overview Of ARCT-810 Phase 2 Clinical Program For Ornithine Transcarbamylase Deficiency And Arcturus’ mRNA Liver Therapeutics Platform On Sept. 23
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today
National Beverage Posts Downbeat Q1 Results, Joins Zumiez, Adobe And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures rose, while National Beverage and several stocks fell premarket after disappointing results, led by Zumiez down 15.7%.
Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 9:20 AM EDTCompany ParticipantsJoseph Payne -...
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-05 | Markels John | +15,000 | - | - |
| 2026-06-05 | Marantz Jing L. | +15,000 | - | - |
| 2026-06-05 | Slaoui Moncef | +15,000 | - | - |
| 2026-06-05 | Marquet Magda | +15,000 | - | - |
| 2026-06-05 | HOLMES EDWARD W | +15,000 | - | - |
| 2026-06-05 | BARLOW JAMES F | +15,000 | - | - |
| 2026-06-05 | FARRELL PETER C | +15,000 | - | - |
| 2026-05-01 | MULROY DENNIS | +100,000 | - | - |
| 2025-12-17 | Roberts Joseph | +10,000 | - | - |
| 2025-12-17 | Kurata Lance | +54,000 | - | - |
| 2025-12-17 | Chivukula Pad | +54,000 | - | - |
| 2025-12-17 | Payne Joseph E | +175,000 | - | - |